General Information

Stock Quote

ABMD (Common Stock)
Exchange NASDAQ (US Dollar)
Price   $23.64
Change (%)   Stock is Down  0.33  (1.38%)
Volume   77,100
Data as of 10/22/14 4:00 PM ET
Minimum 20 minute delay
Refresh quote

Corporate Profile

Abiomed (NASDAQ: ABMD) is a global technology leader focused on RECOVERING HEARTS AND SAVING LIVES.

Abiomed CEO, Chairman, and President, Michael R. Minogue, has focused the company’s efforts on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.

More>>

More »   Recent News

Date Title  
10/09/14

DANVERS, Mass., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) announced today that on Thursday, October 30, 2014, the Company will release financial results for the second quarter of fiscal 2015. The Company will host a conference call to discuss the results on Thursday, October 30, 2014, at 8:00 a.m. ET. Michael R. Minogue, Chairman...

09/18/14

DANVERS, Mass., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the appointment of Ingrid Goldberg, as Director of Investor Relations.  "We are extremely pleased to have Ingrid on board during a pivotal time of growth and opportunity for the Company," ...

09/16/14

WASHINGTON, Sept. 16, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP™ (Right Percutaneous) System. The clinical trial results demonstrated a survival ...

09/10/14

DANVERS, Mass., Sept. 10, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced that data from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP™ (Right Peripheral) System, will be released during the scientific sessions at the Cardiovascula...

09/03/14

DANVERS, Mass., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on September 10, 2014 at 10:20 a.m. EDT. The conferenc...